Evidence map›Paper›PMID 34294833›Full record

ArticleScientific reports2021

Identification of prognostic alternative splicing events in sarcoma.

Hongshuai Li, Jie Yang, Guohui Yang, Jia Ren, Yu Meng, Peiyi Qi, Nan Wang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A new molecular subclassification andFrontiers in pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hongshuai Li *Department of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jie Yang *Department of Operation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Guohui YangDepartment of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jia RenDepartment of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Yu MengDepartment of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Peiyi QiDepartment of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Nan WangDepartment of Emergency Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. alpha19820607@163.com.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcoma is a rare malignancy with unfavorable prognoses. Accumulating evidence indicates that aberrant alternative splicing (AS) events are generally involved in cancer pathogenesis. The aim of this study was to identify the prognostic value of AS-related survival genes as potential biomarkers, and highlight the functional roles of AS events in sarcoma. RNA-sequencing and AS-event datasets were downloaded from The Cancer Genome Atlas (TCGA) sarcoma cohort and TCGA SpliceSeq, respectively. Survival-related AS events were further assessed using a univariate analysis. A multivariate Cox regression analysis was also performed to establish a survival-gene signature to predict patient survival, and the area-under-the-curve method was used to evaluate prognostic reliability. KOBAS 3.0 and Cytoscape were used to functionally annotate AS-related genes and to assess their network interactions. We detected 9674 AS events in 40,184 genes from 236 sarcoma samples, and the 15 most significant genes were then used to construct a survival regression model. We further validated the involvement of ten potential survival-related genes (TUBB3, TRIM69, ZNFX1, VAV1, KCNN2, VGLL3, AK7, ARMC4, LRRC1, and CRIP1) in the occurrence and development of sarcoma. Multivariate survival model analyses were also performed, and validated that a model using these ten genes provided good classifications for predicting patient outcomes. The present study has increased our understanding of AS events in sarcoma, and the gene-based model using AS-related events may serve as a potential predictor to determine the survival of sarcoma patients.

Indexed as

Alternative SplicingGene Regulatory NetworksArea Under CurveDatabases, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMultivariate AnalysisPrognosisSarcomaSequence Analysis, RNASurvival Analysis

Identifiers

PMID34294833
PMCPMC8298452
OpenAlexW3183893778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.